Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis
- PMID: 11927715
- DOI: 10.1542/peds.109.4.678
Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis
Abstract
Objective: Childhood diarrhea accounts for substantial morbidity and mortality worldwide. Multiple studies in children have shown that Lactobacillus, administered orally, may have antidiarrheal properties. We conducted a meta-analysis of randomized, controlled studies to assess whether treatment with Lactobacillus improves clinical outcomes in children with acute infectious diarrhea.
Methods: Studies were sought in bibliographic databases of traditional biomedical as well as complementary and alternative medicine literature published from 1966 to 2000. Search terms were "competitive inhibition," "diarrhea," "gastroenteritis," "Lactobacillus," "probiotic," "rotavirus," and "yog(h)urt." We included studies that were adequately randomized, blinded, controlled trials in which the treatment group received Lactobacillus and the control group received an adequate placebo and that reported clinical outcome measures of diarrhea intensity. These inclusion criteria were applied by blind review and consensus. The original search yielded 26 studies, 9 of which met the criteria. Multiple observers independently extracted study characteristics and clinical outcomes. Data sufficient to perform meta-analysis of the effect of Lactobacillus on diarrhea duration and diarrhea frequency on day 2 were contained in 7 and 3 of the included studies, respectively.
Results: Summary point estimates indicate a reduction in diarrhea duration of 0.7 days (95% confidence interval: 0.3-1.2 days) and a reduction in diarrhea frequency of 1.6 stools on day 2 of treatment (95% confidence interval: 0.7-2.6 fewer stools) in the participants who received Lactobacillus compared with those who received placebo. Details of treatment protocols varied among the studies. A preplanned subanalysis suggests a dose-effect relationship.
Conclusion: The results of this meta-analysis suggest that Lactobacillus is safe and effective as a treatment for children with acute infectious diarrhea.
Comment in
-
Review: Lactobacillus is safe and effective for treating children with acute infectious diarrhea.ACP J Club. 2002 Nov-Dec;137(3):96. ACP J Club. 2002. PMID: 12418836 No abstract available.
Similar articles
-
Probiotics for the prevention of pediatric antibiotic-associated diarrhea.Cochrane Database Syst Rev. 2015 Dec 22;(12):CD004827. doi: 10.1002/14651858.CD004827.pub4. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2019 Apr 30;4:CD004827. doi: 10.1002/14651858.CD004827.pub5 PMID: 26695080 Updated. Review.
-
Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials.J Pediatr Gastroenterol Nutr. 2001 Oct;33 Suppl 2:S17-25. doi: 10.1097/00005176-200110002-00004. J Pediatr Gastroenterol Nutr. 2001. PMID: 11698781 Review.
-
Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis.N Engl J Med. 2018 Nov 22;379(21):2015-2026. doi: 10.1056/NEJMoa1802597. N Engl J Med. 2018. PMID: 30462939 Clinical Trial.
-
A Double-blind, Randomized, Placebo-controlled Trial of Lactobacillus acidophilus for the Treatment of Acute Watery Diarrhea in Vietnamese Children.Pediatr Infect Dis J. 2018 Jan;37(1):35-42. doi: 10.1097/INF.0000000000001712. Pediatr Infect Dis J. 2018. PMID: 28787388 Free PMC article. Clinical Trial.
-
Probiotics for prevention and treatment of diarrhea.J Clin Gastroenterol. 2011 Nov;45 Suppl:S149-53. doi: 10.1097/MCG.0b013e3182257e98. J Clin Gastroenterol. 2011. PMID: 21992955 Review.
Cited by
-
Computational prediction of new therapeutic effects of probiotics.Sci Rep. 2024 May 24;14(1):11932. doi: 10.1038/s41598-024-62796-4. Sci Rep. 2024. PMID: 38789535 Free PMC article.
-
Updates on the Role of Probiotics against Different Health Issues: Focus on Lactobacillus.Int J Mol Sci. 2022 Dec 21;24(1):142. doi: 10.3390/ijms24010142. Int J Mol Sci. 2022. PMID: 36613586 Free PMC article. Review.
-
Valorization of leftover green tea residues through conversion to bioactive peptides using probiotics-aided anaerobic digestion.Microb Biotechnol. 2023 Feb;16(2):418-431. doi: 10.1111/1751-7915.14155. Epub 2022 Oct 26. Microb Biotechnol. 2023. PMID: 36285915 Free PMC article.
-
The clinical evidence for postbiotics as microbial therapeutics.Gut Microbes. 2022 Jan-Dec;14(1):2117508. doi: 10.1080/19490976.2022.2117508. Gut Microbes. 2022. PMID: 36184735 Free PMC article. Review.
-
Neonatal microbiota-epithelial interactions that impact infection.Front Microbiol. 2022 Aug 25;13:955051. doi: 10.3389/fmicb.2022.955051. eCollection 2022. Front Microbiol. 2022. PMID: 36090061 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
